Skip to main content

Table 1 Demographic and clinical characteristics of patients

From: Prevalence of autoantibodies in patients with juvenile idiopathic arthritis: results from the German inception cohort ICON-JIA

Patients (n)

499

Gender

Female n (%)

333 (66.7)

median (range)

n (%)

Age (years)

at blood collection

11 (3–22)

3–10 years

11–22 years

228 (45.7)

270 (54.3)

at study inclusion

7 (< 1–17)

 

at onset of disease

6.0 (< 1–16.4)

 

median (range)

n (%)

Disease duration at time of blood collection (years)

4.4 (0.9–14.1)

< 4.5 years

> 4.5 years

256 (51.3)

240 (48.1)

Disease activity score (cJADAS-10)

3.0 (0.5–25)

 

no data

n = 164

  

n (%)

Treatment

ever before blood collection

at time of blood collection

csDMARDs

427 (85.6)

274 (54.9)

bDMARDs

206 (41.3)

140 (28.1)

Glucocorticoide therapy

442 (84.6)

82 (16.4)

  

n (%)

JIA categories

systemic arthritis

16 (3.2)

oligoarthritis, extended

49 (9.8)

oligoarthritis, persistent

168 (33.7)

psoriatic arthritis

27 (5.4)

enthesitis-related arthritis

52 (10.4)

polyarthritis, seropositive

10 (2.0)

polyarthritis, seronegative

142 (28.5)

undifferentiated arthritis

34 (6.8)

no data

1 (0.2)

Physician reported ANA positive patients at inclusion

310 (62.1)

  1. csDMARD: conventional synthetic disease-modifying antirheumatic drug; bDMARD: biologic disease-modifying antirheumatic drug